Abstract:Neuroblastoma is the most common extracranial solid tumor in children and arises from anywhere along the sympathetic nervous system. It is a highly heterogeneous disease with a wide range of prognosis, from spontaneous regression or maturing to highly aggressive. About half of pediatric neuroblastoma patients develop the metastatic disease at diagnosis, which carries a poor prognosis. Nuclear medicine plays a pivotal role in the diagnosis, staging, response assessment, and long-term follow-up of neuroblastoma. And it has also played a prominent role in the treatment of neuroblastoma. Because the structure of metaiodobenzylguanidine (MIBG) is similar to that of norepinephrine, 90% of neuroblastomas are MIBG-avid. 123I-MIBG whole-body scintigraphy is the standard nuclear imaging technique for neuroblastoma, usually in combination with SPECT/CT. However, approximately 10% of neuroblastomas are MIBG nonavid. PET imaging has many technical advantages over SPECT imaging, such as higher spatial and temporal resolution, higher sensitivity, superior quantitative capability, and whole-body tomographic imaging. In recent years, various tracers have been used for imaging neuroblastoma with PET. The importance of patient-specific targeted radionuclide therapy for neuroblastoma therapy has also increased. 131I-MIBG therapy is part of the front-line treatment for children with high-risk neuroblastoma. And peptide receptor radionuclide therapy with radionuclide-labeled somatostatin analogues has been successfully used in the therapy of neuroblastoma. Moreover, radioimmunoimaging has important applications in the diagnosis of neuroblastoma, and radioimmunotherapy may provide a novel treatment modality against neuroblastoma. This review discusses the use of current and novel radiopharmaceuticals in nuclear medicine imaging and therapy of neuroblastoma.

Research advances of MYCN and ALK gene-related targeted drugs in the treatment of neuroblastoma

Research frontiers and reflections on neuroblastoma

Advancing therapy for neuroblastoma

The roles played by the MYCN, Trk, and ALK genes in neuroblastoma and neural development

Recent advances in molecular genetic characterization of high-risk neuroblastoma

Nanotechnology-Based Diagnostic and Therapeutic Strategies for Neuroblastoma

Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors

Research therapeutic advances of oncolytic virus for neuroblastoma

Progress of Oncolytic Virotherapy for Neuroblastoma

Neuroblastoma: clinical and biological approach to risk stratification and treatment

Current Status and Future Perspective on Molecular Imaging and Treatment of Neuroblastoma

Pathogenesis, Biomarkers and Therapeutic Targets

[Research Progress in the Efficacy and Safety of ALK Inhibitors in the Treatment of NSCLC Brain Metastasis]

Advances in Neuroblastoma Immunotherapy Based on Chimeric Antigen Receptor

Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions

A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins

Anti-cancer Effect of Oncolytic Adenovirus-Armed Shrna Targeting MYCN Gene on Doxorubicin-Resistant Neuroblastoma Cells.

Advances in research on anaplastic lympgoma kinase inhibitors

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation

Advances in the Treatment of Medulloblastomas

Abstract B22: Antitumor effects of selective PRMT1 inhibitors on neuroblastoma in vitro and in vivo